Introduction {#S0001}
============

In the management of multiple sclerosis (MS), a wide variety of new disease-modifying therapies (DMT) have been recently introduced what brings new opportunities for individualized therapy, where patients and healthcare providers must balance considerations of efficacy, side effects and long-term impact in a shared decision process.[@CIT0001] As a result, patients' preferences become more important in decision-making.[@CIT0002] Since MS is a debilitating life-long condition seriously affecting the quality of life and the clinical outcome is directly related to patient adherence to treatment,[@CIT0003]--[@CIT0008] high patient satisfaction with the chosen DMT plays a key role in successful MS management.

In the real world, the DMT selection for an individual patient is affected by approved labelling, availability in a particular country, local treatment guidelines and/or reimbursement criteria. In Slovakia, DMT selection is mainly driven by the reimbursement criteria when the health-care payer approves a chosen DMT for an individual patient. At the time of data collection for this study, from May 2016 to March 2017, Slovakian reimbursement criteria considered interferons, glatiramer acetate, teriflunomide and dimethyl fumarate as equals for the initiation of relapsing-remitting multiple sclerosis (RRMS) treatment. A DMT switch was allowed for inadequate efficacy - no decrease of relapse rate, the presence of a Gd+T1 lesion or a significant increase of T2 lesions, or an increase in the Expanded Disability Status Scale (EDSS) score by ≥1 point while on treatment. Two DMTs from this 1st line group had to be introduced before escalation to DMTs with higher efficacy (fingolimod and natalizumab). According to reimbursement criteria, alemtuzumab was reserved for patients who failed three DMTs with different modes of action. Since 1 January 2016, dimethyl fumarate can be prescribed only to patients with a persistent 3-month EDSS change after relapse, regardless of treatment by corticosteroids or the presence of a Gd+ T1 lesion or infratentorial localization of lesions, or to patients who have failed two DMTs with different mechanisms of action. For rapidly evolved MS (two relapses within 12 months and the presence of a Gd+T1 lesion or a significant increase of T2 lesions), fingolimod and/or natalizumab or alemtuzumab (from 1 January 2017) were recommended as the first-choice treatment.

The primary objective of the SKARLET study was to assess the treatment satisfaction with DMTs in real-life setting using the TSQM 9 in patients with RRMS in routine clinical care in Slovakia. Here we also report the results of secondary objectives to characterize treatment patterns and relationships of DMT dosage form with TSQM scores.

Patients and Methods {#S0002}
====================

Patient Population {#S0002-S2001}
------------------

The study was conducted in 10 out-patient centers specialized in the treatment of MS across Slovakia.

The study population consisted of adult patients (≥18 years of age) diagnosed with RRMS according to revised McDonald 2010 criteria[@CIT0009] who had been receiving DMT for ≥ 3 months and ≤ 2 years in real-life clinical practice, and in accordance with Summary of Product Characteristics and standard clinical practice. Patients had to be able to fulfil questionnaires independently, and sign and date informed consent before undergoing any study-specific procedure. Repeated participation in the SKARLET registry was not allowed.

Study Objectives {#S0002-S2002}
----------------

The primary objective of the study was to assess the treatment satisfaction with DMT in real-life settings using descriptive statistics of the TSQM 9 scores in patients with RRMS in routine clinical care in Slovakia. TSQM 9 was created from TSQM Version 1.4 but without the five items from the domain of side effects that has the potential to interfere with routine clinical care. TSQM-9 consists of three domains: the effectiveness scale (3 questions), the convenience scale (3 questions) and the global satisfaction scale (3 questions).[@CIT0010] Scores range from 0 to 100; higher scores indicate greater satisfaction. TSQM scores were assessed for all DMTs in total, separately for each route of administration (oral, injection, infusion), and separately for each DMT if used by more than 10 patients to avoid bias caused by a small number of patients in the relevant subgroup. Furthermore, the following endpoints were collected to characterize treatment patterns in DMTs for RRMS in the real-world: current DMT, any previous DMT, reason for discontinuing a previous DMT, the duration of a previous DMT, dosage form of the previous and current DMT, and EDSS[@CIT0011] at the start and end of each DMT.

Study Design/Data Collection {#S0002-S2003}
----------------------------

SKARLET was a non-interventional, cross-sectional study in Slovakia conducted from 2 May 2016 to 1 March 2017.

This registry was performed in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice,[@CIT0012] the Declaration of Helsinki,[@CIT0013] and any applicable local laws and regulations. Ethical committee of Faculty of Medicine, Comenius University and University Hospital Bratislava, Old Town Hospital approved the study before enrollment of the first patient.

Eligible patients who agreed to participate in the study and signed the informed consent form were enrolled on a consecutive basis during their routine office visits. During the only study-related visit (V1), they completed the TSQM 9 questionnaire, and answered questions about satisfaction with current therapy in comparison to the previous therapy (if treated with more than one DMT). Other required information was recorded from the medical documentation retrospectively. Data entered into the electronic Case Report Forms (eCRFs) were reviewed by data management for completeness and accuracy. In the case of any irregularity, additional queries were generated by the data manager to make any required corrections or additions. Furthermore, random data quality control was performed by a qualified site monitor for 5% of records on-site.

Statistics {#S0002-S2004}
----------

The analysis of collected data was based on descriptive statistics including absolute and relative frequencies of discrete variables. Continuous variables were described by: count, mean, standard deviation, median, minimum, maximum and 2-sided 95% confidence interval (CI) of the mean. Discrete variables were described by: count and percentages. Null hypotheses that there is no difference in TSQM 9 scores among different dosage forms of DMT were tested by independent samples Kruskal--Wallis Test at the level of significance of 0.05. Normal distribution of the data was excluded by Shapiro--Wilk test also at the level of significance of 0.05.

Results {#S0003}
=======

Overall, 424 patients were screened and 417 were enrolled and evaluable for the primary analysis. This sample size corresponds to approximately 10% of the treated MS population in Slovakia.

Demographic and baseline disease characteristics of the study population are summarized in [Table 1](#T0001){ref-type="table"}. The gender ratio (males: females) was 1:2 (32.6%:67.4%) with no major difference among individual drugs, except for glatiramer acetate with nearly 80% of female users. 72% of patients had an EDSS within the range 0--3. Table 1Demographic and Baseline Disease CharacteristicsCharacteristicsN=417Minimum; MaximumAge, mean (SD), years38.85 (11.07)19; 69Female, n (%)281 (67.4%)EDSS score, mean (SD)2.59 (1.24)0.0; 5.5Duration of MS mean (SD), months66.49 (60.29)1; 402Number of previous MS medication, n (%) None185 (44.4%) 1135 (32.4%) 265 (15.6%) 326 (6.2%) 44 (1.0%) 52 (0.5%)Total number of relapses treated with corticoids experienced by a patient, mean (SD)3.14 (2.24)0; 15Number of clinical relapses in last 12 months, mean (SD)0.65 (0.72)0; 4Number of clinical relapses in last 24 months, mean (SD)1.36 (0.96)0; 4

The distribution of current DMT treatment is summarized in [Table 2](#T0002){ref-type="table"}. Table 2Proportion of Patient by Current DMTCurrent DMTDosage Formn%Teriflunomideoral8119.4%Interferon beta-1a (subcutaneous -- SC)injections7117.0%Fingolimodoral5813.9%Dimethyl fumarateoral5112.2%Glatiramer acetate 40 mginjections4410.6%Natalizumabinfusion419.8%Interferon beta-1a (intramuscular -- IM)injections225.3%Interferon beta-1b (Novartis)injections174.1%Alemtuzumabinfusion102.4%Glatiramer acetate 20 mginjections81.9%Peginterferon beta-1ainjections81.9%Interferon beta-1b (Bayer)injections41.0%Unknown treatment20.5%Total417100.0%

Out of 417 patients, 185 (44.4%) were newly diagnosed patients on their first DMT. 232 patients (55.6%) had received a previous DMT. Overall, 367 DMT switches in total were reported in the SKARLET study. Reasons for discontinuing a previous DMT are summarized in [Table 3](#T0003){ref-type="table"}. Disease activity accounted for 68% of DMT switches. The mean EDSS change during a previous treatment until a switch was 0.558 (95% CI: 0.480--0.636). According to single question asking patients with a DMT switch to evaluate the new DMT in comparison to the previous one, patients were generally satisfied with their treatment switch, with 82.6% patients more satisfied with the current treatment than the previous, 14.8% patients were equally satisfied with current and previous treatments, and 2.7% were more satisfied with the previous treatment than the current treatment. Table 3Reasons for Discontinuing a Previous DMTReasons for Discontinuing a DMTn%Unchanged or increased number of relapses during 12 months compared with the previous treatment9225.1%MRI activity defined as 2 or more new T2 lesions and 1 or more T1 Gd+ lesions9124.8%Increase of 1 point in EDSS during 12 months before end of treatment6517.7%Patient request133.5%Administrative reasons133.5%Immunological contraindication113.0%Absence of MxA protein expression evaluated every 2 years from the start of treatment (only for interferons)92.5%Other3910.6%Unknown349.3%Total367100%

The median duration of any previous DMT was 2 years (mean 33.6 months with 95% CI: 30.56--36.82 months).

When evaluating the last treatment switch with respect to the route of DMT administration, subsequent treatment using the oral form was the most frequent choice (61.2%), followed by switches between injectables (19.0%) and switches to infusions (16.8%) ([Table 4](#T0004){ref-type="table"}). Table 4DMT Switches from the Last Previous DMT to the Current DMT by Dosage FormFromTon%OralOral104.3%Injection31.3%Infusion177.3%InjectionOral12252.6%Injection4419.0%Infusion187.8%InfusionOral104.3%Injection00.0%Infusion41.7%Missing41.7%Total232100%

Three parameters of TSQM 9, effectiveness, convenience and global satisfaction, were analyzed separately for all DMTs in total, for DMTs by the route of administration and separately for each DMT. When assessing all DMTs in total ([Table 5](#T0005){ref-type="table"}), the highest score (mean; 95% CI) was reported for convenience (75.05; 73.49--76.61), followed by effectiveness (68.15; 66.56--69.75), with the lowest for global satisfaction (66.94; 65.26--68.62).Table 5TSQM 9 Scores of the Current DMT by Dosage Form -- Effectiveness, Convenience and Global SatisfactionDMT Dosage FormnEffectivenessConvenienceGlobal SatisfactionMean (95% CI)Mean (95% CI)Mean (95% CI)Oral19068.51 (66.04; 70.97)82.66 (80.59; 84.73)68.76 (66.32; 71.20)Injection17466.79 (64.41; 69.18)66.92 (64.81; 69.04)63.83 (61.45; 66.21)Infusion5171.46 (66.99; 75.93)74.40 (70.12; 78.69)70.73 (64.58; 76.88)Total415\*68.15 (66.56; 69.75)75.05 (73.49; 76.61)66.94 (65.26; 68.62)[^1]

TSQM 9 parameters analyzed separately by route of DMT administration are summarized in [Table 5](#T0005){ref-type="table"}, with infusions rated best for effectiveness and global satisfaction in comparison to oral dosage and injections. For convenience (mean; 95% CI), oral forms were appraised highly (82.66; 80.59--84.73), followed by infusions (74.40, 70.12--78.69), while injections were rated as the worst (66.92; 64.81--69.04).

The difference of TSQM 9 scores by the DMT route of administration is statistically significant for convenience (p \< 0.0001) and global satisfaction (p = 0.004), but not for effectiveness (p = 0.185).

Furthermore, we evaluated TSQM-9 scores separately for each DMT ([Table 6](#T0006){ref-type="table"}). To avoid bias caused by a small number of patients, we included only DMTs used by more than 10 patients. The greatest difference among DMTs was for convenience, with a range from 85.12 (teriflunomide) to 65.36 (interferon beta-1b). Global satisfaction ranged from 71.25 (natalizumab) to 62.18 (interferon beta-1b) and effectiveness from 71.95 (natalizumab) to 65.41 (interferon beta-1a subcutaneous). Table 6TSQM 9 Scores for Each Current DMT and in TotalCurrent DMTnEffectiveness Mean (95% CI)Convenience Mean (95% CI)Global Satisfaction Mean (95% CI)Teriflunomide8167.15 (62.80; 71.50)85.12 (82.07; 88.16)69.58 (65.56;73.59)Interferon beta-1a SC7165.41 (61.28; 69.55)67.37 (63.53; 71.21)63.58 (59.26; 67.91Fingolimod5869.64 (65.68; 73.59)81.70 (77.68; 85.73)68.47 (64.27; 72.68)Dimethyl fumarate5169.39 (65.04; 73.74)79.85 (75.88; 83.81)67.79 (63.13; 72.44)Glatiramer acetate 40 mg4468.56 (65.60;71.52)66.92 (63.70; 70.14)65.58 (62.10; 69.07)Natalizumab4171.95 (67.33; 76.57)74.80 (70.46; 79.13)71.25 (65.74; 76.77)Interferon beta-1a IM2268.18 (59.05; 77.31)66.41 (59.14; 73.68)64.29 (56.47; 72.10)Interferon beta-1b1767.65 (60.56; 74.73)65.36 (59.09; 71.63)62.18 (54.42; 69.95)**Total**415\*68.15 (66.56; 69.75)75.05 (73.49; 76.61)66.94 (65.26; 68.62)[^2]

Discussion {#S0004}
==========

The rapid increase in the number of disease-modifying drugs for MS makes treatment decisions in all phases of the disease very complex. Treatment satisfaction for medication is a patient-reported outcome that gives valuable information on both the patient's perception of current treatment and the differentiation among alternative treatments. In the past decade, several papers have reported on MS patient treatment satisfaction with DMT in various countries.[@CIT0014]--[@CIT0020] Since a patient's treatment experience is to a certain extent influenced by the local availability of particular drugs, country-specific data are needed. To the best of our knowledge, the study presented here is the first report dealing with treatment satisfaction in the Slovak MS population.

The SKARLET study patient population is similar to populations of MS patients described in previous studies,[@CIT0014],[@CIT0021],[@CIT0022] where MS predominantly affects females and young people. In the SKARLET study, there were more females than males (67.4% women) and the average age was 38.85 years, in comparison to the Polish study[@CIT0021] with 69.7% women and an average age of 37.8 years, or an American study[@CIT0022] with 71.6% women and an average age of 48.9 years. The EDSS and duration of MS are also comparable -- SKARLET study: EDSS 2.6, duration of MS 5.5 years; Polish study:[@CIT0021] EDSS 3.2, duration 14.5 years.

TSQM as the primary parameter was used in the study of Glanz et al,[@CIT0016] who separately evaluated different DMTs (intramuscular interferon beta 1a - IFNβ-1a IM, subcutaneous interferon beta 1a - IFNβ-1a SC, glatiramer acetate, and natalizumab) in patients with RRMS. Among DMTs, overall treatment satisfaction was similar, but there were differences in terms of satisfaction with effectiveness, side effects, and convenience. Natalizumab-treated participants reported greater satisfaction with the ability of the medication to treat or prevent their condition than IFNβ-1a IM-treated participants. In terms of convenience, the natalizumab group reported significantly higher overall convenience scores than the IFNβ-1a IM group and greater satisfaction with the ease of use of the medication than the other groups. These findings are in accordance with the SKARLET study results. However, the SKARLET study included also oral DMTs aside from infusions and injections.

A similar study was done by Haase et al,[@CIT0014] for patients with clinically isolated syndrome (CIS) and RRMS who used a first-line DMT (IFNβ-1a IM, IFNβ-1a SC, IFNβ-1b SC, glatiramer acetate) administered by injections in Germany. Differences between current medications were found for convenience scores but not for effectiveness, satisfaction or adherence. Higher global satisfaction and effectiveness were associated with fewer relapses, longer duration of medication, lower disability score and the absence of several side effects.

When compared with the conventional injectable therapies, the oral teriflunomide achieved substantially higher satisfaction on TSQM in the TENERE study,[@CIT0023] since all scores were substantially higher (depending on the dose) with effectiveness rated at 63--67 points, convenience at 88--90 points and global satisfaction at 68--69 points. In the SKARLET study, teriflunomide was rated with a mean 67.15 points for effectiveness, 85.12 points for convenience and 69.58 points for global satisfaction.

Treatment satisfaction reported by patients receiving teriflunomide for 48 weeks was the primary endpoint of the Teri-PRO study.[@CIT0017] The following TSQM scores were reported for the whole study population (1001 patients): global satisfaction 68.2, effectiveness 66.3 and convenience 90.4.

Satisfaction with fingolimod was evaluated by Hanson et al,[@CIT0015] with the following results: convenience (71.7), effectiveness (70.1) and global satisfaction (68.9); in total, 310 patients were included in the study. In the SKARLET study, fingolimod was rated with a mean 69.64 points for effectiveness, 81.70 points for convenience and 68.47 points for global satisfaction.

In the publication on the EPOC study[@CIT0024] that compared the switch from glatiramer acetate or beta interferons to fingolimod versus staying on the injectable DMT, no absolute TSQM values were reported. However, patients switched to oral therapy improved on the effectiveness scale depending on the original injectable DMT by 12--18 points and on the convenience scale by 38--44 points (values for global satisfaction were not given). In the SKARLET study, the difference in the mean scale for effectiveness between oral and injection DMT was 1.72 points and 15.74 for convenience.

A recently published study on treatment satisfaction with injectable DMT in Spain[@CIT0019] reported an effectiveness score of 66.8, convenience 72.5 and global satisfaction 68.8. These scores for convenience and global satisfaction are slightly higher than in the SKARLET study (convenience 66.9, global satisfaction 63.8), but this is in line with our assumptions on country-specific differences.

There are several limitations associated with this study. First, the sample size was relatively small, which could limit the generalizability of the results. Second, the injectable DMTs were not distinguished by intramuscular versus subcutaneous administration or by administration with an auto-injector pen. However, the strength of the study is the implementation of oral and infusion administration forms of DMTs, as opposed to for injectable DMTs there is little information published on these two types of DMT. Third, there are little data on the psychometric qualities of the TSQM, and it has not been validated for use with MS patients.[@CIT0016] Fourth, we did not consider different characteristics of populations treated with injectables, orals or infusions when especially disease activity had to be much higher in patients receiving infusions. Also information given to patient by physician probably highly influences how patients evaluate their treatment. However, it is satisfaction as subjectively perceived by a patient that strongly correlates with treatment adherence and outcome and TSQM represents an efficient tool to measure it. Fifth, the study did not include any measures of adherence and its correlation with treatment satisfaction. Last but not least, we limited DMT duration of ≤ 2 years in our study population as we aimed to capture current trends in MS treatment. As a result, we omitted patients who take their DMT longer and are probably stable and satisfied with their treatment.

In conclusion, the results of this detailed survey increase our understanding of RRMS patient population characteristics, patient satisfaction with DMT treatment and treatment practice of MS specialists in Slovakia. This study confirmed that patients find oral DMT to be most convenient. However, the infusion form of treatment outweighed oral DMTs in global satisfaction and effectiveness, as both DMTs administered by infusions (alemtuzumab and natalizumab) are highly effective MS therapy options. For the future, longitudinal comparative studies are needed to confirm the current findings, measure long-term satisfaction, deeply investigate factors that influence patient satisfaction and assess patient preferences across a range of treatment options.
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[^1]: **Note:** \*2 patients with unknown current DMT were omitted.

[^2]: **Note:** \*2 patients with unknown current DMT were omitted.
